Skip to main content

The first microalgae platform for the production of anticancer biopharmaceuticals

Project description

Microalgae powerhouses do it better when it comes to production of anticancer therapeutics

Demand for recombinant pharmaceutical proteins is growing globally and the use of microorganisms as small bioreactors for rapid and cost-effective production is an important area of research. Microalgae, like mammalian cell lines, enable post-transcriptional and post-translational modifications, high production quality and high protein yield. However, unlike mammalian cell culture, they offer fast large-scale production, low overall cost, low risk of contamination, and easy reproduction and distribution. MABIOS has developed a microalgae platform for producing anticancer biopharmaceuticals that could lower the cost of treatment for millions of patients worldwide. EU-funding is providing the opportunity to develop the best business plan, meet regulatory requirements, and bring the platform to market.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 50 000,00
Bargelaan 200
2333 CW Leiden

See on map

West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 21 429,00